Ann: Response to ASX Query, page-70

To me it’s pretty clear that ADO paid consulting fees to an external source (in order to progress their ongoing business activities) and was making the point to the ASX that this resulted in higher than normal expenses incurred in the quarter

On the flip side, they halted their European clinical trial in order to conserve future expenses.

So both these responses relate to company expenditure in my view.

The only cash coming into the company is the $3.2m R&D rebate clearly highlighted in the Announcement.

Happy to be proven wrong.

H